Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial
Status:
Withdrawn
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
Patients with advanced soft tissue sarcoma(rhabdomyosarcoma and liposarcoma excluded), who
experience progression after standard chemotherapy, have limited treatment options which
promise a survival benefit.This trial tends to explore apatinib, which is a domestic highly
selective inhibitor of vascular endothelial growth factor receptor-2, as a treatment option
for heavily pretreated soft tissue sarcoma patients.
Phase:
Phase 2
Details
Lead Sponsor:
Peking University People's Hospital
Collaborators:
Peking University International Hospital Peking University Shougang Hospital